What eXoZymes Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 5 | 5 |
| Sells | 1 | 3 |
| Total trades | 9 | 16 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 33,230 | 57,447 |
| Disposed | 3,729 | 5,229 |
| Net activity | +29,501 | +52,218 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Perriman Damien Alan | Chief Commercial Officer | Oct 12 | Sale for tax withholding · S | −3,729 | $5.21 | −$19.4K | 28,692 |
| Perriman Damien Alan | Chief Commercial Officer | Oct 09 | Exercise / conversion · M | +3,922 | — | — | 32,421 |
| Heltzen Michael | Chief Executive Officer | Aug 26 | Open-market buy · P | +250 | $7.60 | +$1.9K | 14,453 |
| Heltzen Michael | Chief Executive Officer | Aug 26 | Open-market buy · P | +251 | $7.35 | +$1.84K | 14,704 |
| Heltzen Michael | Chief Executive Officer | Aug 26 | Open-market buy · P | +4 | $7.58 | +$30.3 | 14,708 |
| Heltzen Michael | Chief Executive Officer | Aug 25 | Open-market buy · P | +100 | $7.50 | +$750 | 13,953 |
| Heltzen Michael | Chief Executive Officer | Aug 25 | Open-market buy · P | +250 | $7.52 | +$1.88K | 14,203 |
| Heltzen Michael | Chief Executive Officer | Aug 19 | Grant / award · A | +8,841 | $6.40 | +$56.6K | 13,853 |
| Perriman Damien Alan | Chief Commercial Officer | Aug 19 | Exercise / conversion · M | +19,612 | — | — | 28,499 |
| Korman Tyler Paz | Chief Scientific Officer | Apr 09 | Open-market sale · S | −750 | $10.53 | −$7.89K | 729,123 |
| Korman Tyler Paz | Chief Scientific Officer | Apr 08 | Open-market sale · S | −750 | $10.04 | −$7.53K | 729,873 |
| Opgenorth Paul Hideo | Vice President, Development | Apr 01 | Grant / award · A | +3,999 | $8.44 | +$33.8K | 645,149 |
| Nawaz Fouad | Vice President- Finance | Apr 01 | Grant / award · A | +5,999 | $8.44 | +$50.6K | 9,488 |
| Korman Tyler Paz | Chief Scientific Officer | Apr 01 | Grant / award · A | +5,332 | $8.44 | +$45K | 730,623 |
| Perriman Damien Alan | Chief Commercial Officer | Apr 01 | Grant / award · A | +8,887 | $8.44 | +$75K | 0 |
| Perriman Damien Alan | Chief Commercial Officer | Apr 01 | Grant / award · A | +62,759 | — | — | 62,759 |
| Heltzen Michael | Chief Executive Officer | Jul 02 | Open-market buy · P | +1,040 | $10.22 | +$10.6K | 10,629 |
| Korman Tyler Paz | Vice President, Research | Jun 16 | Grant / award · A | +2,990 | $12.54 | +$37.5K | 725,291 |
| Opgenorth Paul Hideo | Vice President, Development | Jun 13 | Grant / award · A | +2,990 | $12.54 | +$37.5K | 641,150 |
| Nawaz Fouad | Vice President, Finance | Jun 13 | Grant / award · A | +3,489 | $12.54 | +$43.8K | 3,489 |
Loading...
